Nanomedicine: Pharmacological perspectives

Santanu Bhattacharya; Khalid M. Alkharfy; Rajiv Janardhanan; Debabrata Mukhopadhyay

doi:10.1515/ntrev-2011-0010

Nanomedicine: Pharmacological perspectives

Santanu Bhattacharya, Khalid M. Alkharfy, Rajiv Janardhanan, Debabrata Mukhopadhyay

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Rapid developments in the field of nanotechnology are generating enormous interest in prospecting the potential of multifunctional therapeutic nanovectors in the field of personalized medicine. Although the nanomaterials are of same dimensions to many cellular machineries, their interaction with cells, tissues and organs of the body are not well understood. This in turn forms the rationale for a comprehensive study of these nanoplatforms in various disease models in terms of their toxicity, pharmacokinetics, pharmacodynamics, and pharmacogenetics. Such a study will significantly aid in our quest in translating its application from bench to bedside.

Original language	English (US)
Pages (from-to)	235-253
Number of pages	19
Journal	Nanotechnology Reviews
Volume	1
Issue number	3
DOIs	https://doi.org/10.1515/ntrev-2011-0010
State	Published - Jun 1 2012

Keywords

Nanomedicine
Pharmacodynamics
Pharmacogenetics
Pharmacokinetics
Toxicity

ASJC Scopus subject areas

Biotechnology
Medicine (miscellaneous)
Materials Science (miscellaneous)
Energy Engineering and Power Technology
Engineering (miscellaneous)
Process Chemistry and Technology

Access to Document

10.1515/ntrev-2011-0010

Cite this

@article{7679c21635dc43a48daf503d0c836744,

title = "Nanomedicine: Pharmacological perspectives",

abstract = "Rapid developments in the field of nanotechnology are generating enormous interest in prospecting the potential of multifunctional therapeutic nanovectors in the field of personalized medicine. Although the nanomaterials are of same dimensions to many cellular machineries, their interaction with cells, tissues and organs of the body are not well understood. This in turn forms the rationale for a comprehensive study of these nanoplatforms in various disease models in terms of their toxicity, pharmacokinetics, pharmacodynamics, and pharmacogenetics. Such a study will significantly aid in our quest in translating its application from bench to bedside.",

keywords = "Nanomedicine, Pharmacodynamics, Pharmacogenetics, Pharmacokinetics, Toxicity",

author = "Santanu Bhattacharya and Alkharfy, {Khalid M.} and Rajiv Janardhanan and Debabrata Mukhopadhyay",

note = "Publisher Copyright: {\textcopyright} 2012 by Walter de Gruyter.",

year = "2012",

month = jun,

day = "1",

doi = "10.1515/ntrev-2011-0010",

language = "English (US)",

volume = "1",

pages = "235--253",

journal = "Nanotechnology Reviews",

issn = "2191-9089",

publisher = "Walter de Gruyter GmbH",

number = "3",

}

TY - JOUR

T1 - Nanomedicine

T2 - Pharmacological perspectives

AU - Bhattacharya, Santanu

AU - Alkharfy, Khalid M.

AU - Janardhanan, Rajiv

AU - Mukhopadhyay, Debabrata

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Rapid developments in the field of nanotechnology are generating enormous interest in prospecting the potential of multifunctional therapeutic nanovectors in the field of personalized medicine. Although the nanomaterials are of same dimensions to many cellular machineries, their interaction with cells, tissues and organs of the body are not well understood. This in turn forms the rationale for a comprehensive study of these nanoplatforms in various disease models in terms of their toxicity, pharmacokinetics, pharmacodynamics, and pharmacogenetics. Such a study will significantly aid in our quest in translating its application from bench to bedside.

AB - Rapid developments in the field of nanotechnology are generating enormous interest in prospecting the potential of multifunctional therapeutic nanovectors in the field of personalized medicine. Although the nanomaterials are of same dimensions to many cellular machineries, their interaction with cells, tissues and organs of the body are not well understood. This in turn forms the rationale for a comprehensive study of these nanoplatforms in various disease models in terms of their toxicity, pharmacokinetics, pharmacodynamics, and pharmacogenetics. Such a study will significantly aid in our quest in translating its application from bench to bedside.

KW - Nanomedicine

KW - Pharmacodynamics

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84898923080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898923080&partnerID=8YFLogxK

U2 - 10.1515/ntrev-2011-0010

DO - 10.1515/ntrev-2011-0010

M3 - Article

AN - SCOPUS:84898923080

SN - 2191-9089

VL - 1

SP - 235

EP - 253

JO - Nanotechnology Reviews

JF - Nanotechnology Reviews

IS - 3

ER -

Nanomedicine: Pharmacological perspectives

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this